GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Net Income From Continuing Operations

Genenta Science SPA (Genenta Science SPA) Net Income From Continuing Operations : $-12.65 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genenta Science SPA's net income from continuing operations for the six months ended in Dec. 2023 was $-5.33 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.65 Mil.

Genenta Science SPA Net Income From Continuing Operations Historical Data

The historical data trend for Genenta Science SPA's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Net Income From Continuing Operations Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-5.11 -6.80 -6.25 -8.98 -12.70

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only -1.67 -2.23 -6.74 -7.32 -5.33

Genenta Science SPA Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Net Income From Continuing Operations
Comparable Companies
RVPH VXRT PMVP THRX ANIX IFRX BDTX ABEO CDXC INO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
K5F:Germany
Address
Via Olgettina No. 58, Milan, ITA, 20132
Website
https://www.genenta.com
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.